HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipecac’s status

This article was originally published in The Tan Sheet

Executive Summary

Recommendations by FDA's Nonprescription Drugs Advisory Committee meeting June 12 to discontinue Ipecac's OTC status "do not adequately represent the perspective of many practicing medical toxicologists," Richard Dart, MD/PhD, says in July 22 comments filed with the agency (1"The Tan Sheet" June 16, 2003, p. 3). Ipecac is useful in cases of iron and acetaminophen ingestion and for households in rural areas, the Rocky Mountain Poison Center Director argues. Therefore, Dart requests FDA wait until the tentative final monograph for OTC Poison Treatment Drug Products is "adopted before making its decision on the fate of syrup of Ipecac"...

You may also be interested in...



Ipecac OTC Status Withdrawal Advised By NDAC Majority

Ipecac syrup should not retain its OTC status as a treatment for accidental poisonings, a majority of the FDA Nonprescription Drugs Advisory Committee agreed at a June 12 meeting in Bethesda, Md

Exec Chat: eClinical Solutions Clears Muddy Clinical Trial Waters

Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.

Merck Of Germany’s Garijo Highlights COVID-19 Vaccine Effective In Mavenclad-Treated MS

Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.

Topics

UsernamePublicRestriction

Register

RS129694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel